

Competitor Analysis: PPAR Agonists

<https://marketpublishers.com/r/CF0923B7209EN.html>

Date: August 2010

Pages: 45

Price: US\$ 460.00 (Single User License)

ID: CF0923B7209EN

Abstracts

Product description

The present Competitive Intelligence Report about PPAR Agonists provides a competitor evaluation in the field of peroxisome proliferator-activated receptor targeting small molecule agonists for treatment of type 2 diabetes and/or dyslipidemia as of August 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Despite the tremendous attrition rate of PPAR agonist R&D over the last 20 years, the ones in the market are commercially quite successful and spur development of improved successors. The current reassessment of benefit/risk ratio of the classical PPAR gamma agonist rosiglitazone by the FDA and the EMA highlights the need for safer PPAR agonists. One promising approach to achieve effective, but still well tolerated PPAR gamma agonists are selective PPAR gamma modulating agents. Other approaches try to combine PPAR alpha, gamma and delta agonism in one molecule and to find the right balance.

The report includes a compilation of marketed products and current active projects in research and development of PPAR Agonists in type 2 diabetes and/or dyslipidemia. In addition, the report lists company-specific R&D pipelines of PPAR agonists. Competitor projects are listed in a tabular format providing information on:

Drug Codes,

Target / Mechanism of Action,

Class of Compound,

Company,

Product Category,

Indication,

R&D Stage and

additional comments with a hyperlink leading to the source of information.

Index

PPAR alpha Agonists

PPAR gamma Agonists / Insulin Sensitizer

PPAR alpha and gamma Agonists

PPAR delta Agonists

PPAR gamma and delta Agonists

PPAR pan Agonists (alpha, gamma and delta)

Corporate PPAR Agonist Product Portfolios and R&D Pipelines

About La Merie

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low

I would like to order

Product name: Competitor Analysis: PPAR Agonists

Product link: <https://marketpublishers.com/r/CF0923B7209EN.html>

Price: US\$ 460.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CF0923B7209EN.html>